Signal
FDA approves Corcept’s first-in-class drug Lifyorli for platinum-resistant ovarian cancer
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-03-25 19:28 UTCUpdated 2026-03-26 10:48 UTC
rss
clinical_trialsfdaapprovalsdrug_development
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
The FDA has approved Corcept Therapeutics' Lifyorli (relacorilant) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone one to three prior systemic treatments, including at least one with bevacizumab....
Entities
Corcept Therapeutics
Score total
0.98
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- FDA approval follows recent clinical trials demonstrating efficacy in resistant ovarian cancers.
- Addresses an unmet medical need for patients with prior bevacizumab treatment.
- Corcept’s milestone could influence future drug development in this cancer category.
Why it matters
- Lifyorli is the first FDA-approved drug in its class for platinum-resistant ovarian cancer.
- It provides a new treatment option for patients with limited alternatives after prior therapies.
- Represents progress in addressing difficult-to-treat ovarian cancer subtypes.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: medium
Recurring claims
- The FDA approved Lifyorli for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after prior systemic treatments including bevacizumab.
How sources frame it
- News Sources: neutral
Consolidated coverage of Corcept's FDA approval of Lifyorli for platinum-resistant ovarian cancer.
All evidence
All evidence
Corcept gets FDA OK for first-in-class ovarian cancer drug
pharmaphorum · pharmaphorum.com · 2026-03-26 10:48 UTC
The FDA has given the all-clear to Corcept’s class-first Lifyorli (relacorilant) to treat adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal...
Fierce Pharma (All) · fiercepharma.com · 2026-03-25 19:28 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- pharmaphorum (1)
- Fierce Pharma (All) (1)
Top origin domains (this list)
- pharmaphorum.com (1)
- fiercepharma.com (1)